FY2026 EPS Estimates for Freeline Therapeutics Holdings plc Reduced by HC Wainwright (NASDAQ:FRLN)

Freeline Therapeutics Holdings plc (NASDAQ:FRLNGet Rating) – Research analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of Freeline Therapeutics in a note issued to investors on Tuesday, November 22nd. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.27 per share for the year, down from their prior forecast of $0.28. HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Freeline Therapeutics’ current full-year earnings is ($1.65) per share.

Separately, BTIG Research lowered their price objective on Freeline Therapeutics from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, August 11th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Freeline Therapeutics Price Performance

FRLN stock opened at $0.64 on Wednesday. Freeline Therapeutics has a twelve month low of $0.60 and a twelve month high of $2.75. The stock has a market cap of $41.57 million, a P/E ratio of -0.30 and a beta of 0.20. The business’s 50-day moving average price is $0.71 and its 200-day moving average price is $0.80.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC purchased a new position in Freeline Therapeutics in the 1st quarter worth approximately $30,000. Prospera Financial Services Inc lifted its holdings in Freeline Therapeutics by 130.3% in the 1st quarter. Prospera Financial Services Inc now owns 34,650 shares of the company’s stock worth $39,000 after purchasing an additional 19,603 shares in the last quarter. Federated Hermes Inc. lifted its holdings in Freeline Therapeutics by 50.0% in the 1st quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $67,000 after purchasing an additional 20,000 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Freeline Therapeutics by 112.5% in the 1st quarter. Renaissance Technologies LLC now owns 446,412 shares of the company’s stock worth $500,000 after purchasing an additional 236,312 shares in the last quarter. Finally, UBS Group AG purchased a new position in Freeline Therapeutics in the 1st quarter worth approximately $565,000. 58.48% of the stock is owned by hedge funds and other institutional investors.

About Freeline Therapeutics

(Get Rating)

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.

Featured Articles

Earnings History and Estimates for Freeline Therapeutics (NASDAQ:FRLN)

Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.